Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Vivesto AB News

    0,0215 € 0,00% +0,00 €
    08:12:38 Uhr Frankfurt aktualisieren | Orderbuch | Mehr Kurse »
    WKN: 509722
    ISIN: SE0000722365
    Typ: Aktie

    Vivesto AB News

    08.10.21 - DGAP
    Oasmia Pharmaceutical (OASM): Focused on pillars of growth
    Edison Investment Research Limited Oasmia Pharmaceutical (OASM): Focused on pillars of growth 08-Oct-2021 / 10:18 GMT/BST London, UK, 8 October 2021 Oasmia ...
    09.09.20 - DGAP
    Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM)
    Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Oasmia Pharmaceutical (OASM) 09-Sep-2020 / 14:59 GMT/BST London, ...
    09.01.20 - GlobeNewswire
    Oasmia to present at Biotech Showcase in San Francisco
    Oasmia Pharmaceutical AB has been selected to present at the Biotech Showcase Conference and will be presenting its technology on Tuesday 14 January at 15:30 (3:30 pm), ...
    30.12.19 - GlobeNewswire
    New number of shares and votes in Oasmia Pharmaceutical AB (publ)
    The number of shares and votes in Oasmia Pharmaceutical AB (publ) has increased as a result of the preferential rights issue completed in December 2019. As a result of the ...
    30.12.19 - GlobeNewswire
    Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – October 31, 2019
    EVENTS IN SECOND QUARTER Oasmia ADSs were delisted from NASDAQ in the US to reduce complexity and costs. Oasmia recruited two General Managers to its management ...
    09.12.19 - GlobeNewswire
    Final result of the rights issue in Oasmia
    06.12.19 - GlobeNewswire
    Oasmia’s rights issue has been oversubscribed
    27.11.19 - GlobeNewswire
    Correction: The CEO of Oasmia buys subscription rights in the ongoing rights issue
    In a previous press release today, November 27, it was stated that Oasmia Pharmaceutical AB's CEO Sven Rohmann bought 978,944 subscription rights in the company. The ...
    27.11.19 - GlobeNewswire
    The CEO and Chairman of the Board of Oasmia buys subscription rights in the ongoing rights issue
    Oasmia Pharmaceutical AB ("Oasmia" or "the Company") CEO Sven Rohmann and the Chairman of the Board Jörgen Olsson today announced that they have purchased 978,944 ...
    19.11.19 - GlobeNewswire
    Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus
    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States ...
    18.11.19 - GlobeNewswire
    Oasmia invites to investor meetings in connection to the rights issue
    The Board of Directors of Oasmia Pharmaceutical AB (publ) (”Oasmia” or the “Company”) invites to investor meetings in connection to the subscription period of the rights issue which ...
    11.11.19 - GlobeNewswire
    Oasmia resolves on a rights issue of approximately SEK 399 million
    Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States ...
    06.11.19 - GlobeNewswire
    Extraordinary General Meeting in Oasmia Pharmaceutical AB on November 6, 2019
    14.10.19 - GlobeNewswire
    Notice of extraordinary general meeting in Oasmia Pharmaceutical AB
    The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the ...
    14.10.19 - GlobeNewswire
    The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million
    The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the ...
    26.09.19 - GlobeNewswire
    Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019
    This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail.
    26.09.19 - GlobeNewswire
    Oasmia Pharmaceutical AB (publ) Interim report for the period May 1 – July 31, 2019
    EVENTS IN FIRST QUARTER
    18.09.19 - GlobeNewswire
    Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte
    In connection with Oasmia's year-end report in June 2019, the company's Board of Directors made a decision to engage a special examiner, audit firm Deloitte (Svante Forsberg ...
    18.09.19 - GlobeNewswire
    Oasmia presents Q1 report through audiocast on September 26
    Oasmia will hold an audiocast and telephone conference on Thursday 26 September at 10:00 (CET) to present the company's Q1 report for the financial year 2019/2020.
    15.09.19 - GlobeNewswire
    The Nomination Committee's proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019
    Oasmia's Nomination Committee has informed the company of its proposal regarding Board of Directors and auditor ahead of the Annual General Meeting September 26, 2019.

    Newssuche

    Videos

    08:50 Uhr
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »